Ligand Pharmaceuticals Incorporated (LGNXZ)

OTCMKTS · Delayed Price · Currency is USD
0.0024
-0.0004 (-14.29%)
At close: Jan 28, 2026
Market Cap3.66B +65.2%
Revenue (ttm)251.23M +64.8%
Net Income48.58M +7.4%
EPS2.49 +0.8%
Shares Outn/a
PE Ratio75.34
Forward PE22.55
Dividendn/a
Ex-Dividend Daten/a
Volume26,000
Average Volume43,617
Open0.0024
Previous Close0.0028
Day's Range0.0024 - 0.0024
52-Week Range0.0010 - 0.0034
Beta0.71
RSI65.58
Earnings DateFeb 11, 2026

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1987
Employees 68
Stock Exchange OTCMKTS
Ticker Symbol LGNXZ
Full Company Profile

Financial Performance

Financial Statements